semaglutide erectile dysfunction The Impact of Glucagon-like Peptide-1 Receptor Agonists on Function: Friend or Foe? Sex Drive, Erectile Dysfunction, and

How do I choose between Retatrutide and Tirzepatide

This breakdown in the clearance of oxidative stress leads directly to the core pathophysiology of conditions like ME/CFS and Long COVID: profound mitochondrial dysfunction

Tirzepatide's added GIP activity is thought to drive the larger effect on top of the shared GLP-1 pathway though weight loss is only one part of the picture, and semaglutide still has the longer cardiovascular-outcomes track record (more on that below)

It helps the skin stay supple and reduces the likelihood of painful cracks that can sideline your training or daily comfort

Clinical studies on GLP-1 receptor agonists, including Saxenda, Wegovy, Ozempic, and Mounjaro , provide valuable insight into their long-term efficacy: Saxenda (Liraglutide) A 3-year study showed: 56% of participants reached and maintained target weight loss in year one With continuous use, many maintained weight loss over 3 years Success was highest when paired with lifestyle interventions (diet + exercise) Risk of weight regain increased if Saxenda was discontinued without behavioral support Wegovy (Semaglutide) STEP 4 trial (68 weeks) showed: Patients who continued Wegovy maintained a 14.8% weight loss Those who stopped the medication regained about two-thirds of the weight within 1 year Suggests Wegovy is effective long-term , but requires ongoing treatment or strong lifestyle adherence Ozempic (Semaglutide) (used off-label for weight loss) In studies where Ozempic was used weekly: Weight loss was sustained as long as treatment continued Discontinuation led to partial weight regain , though not as rapid as in untreated individuals Works well when paired with structured eating plans Mounjaro (Tirzepatide) Strongest Long-Term Outcome to Date SURMOUNT-1 trial: After 72 weeks , participants lost up to 22.5% of body weight Even after treatment ended, those who adopted lifestyle changes were able to keep the weight off Its dual action on both GLP-1 and GIP receptors improves: Insulin sensitivity Appetite regulation Metabolism regulation Early data suggests Mounjaro has the lowest likelihood of rebound weight gain , especially when combined with follow-up care Comparing Saxenda, Wegovy, Ozempic, and Mounjaro 1